Lornoxicam in the treatment of acute and chronic musculoskeletal pain
https://doi.org/10.14412/1996-7012-2022-4-117-121
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used type of drugs in the world and are prescribed for a wide range of indications, including osteoarthritis, rheumatoid arthritis, other diseases of the musculoskeletal system and soft tissues, as well as for the relief of postoperative pain. It is well known that the use of NSAIDs is associated with the risk of gastrointestinal (GIT), cardiovascular (CVS) and kidneys complications. Lornoxicam belongs to the NSAIDs of the oxicam class and is a balanced inhibitor of both cyclooxygenase (COX) isoforms – COX1 and COX2 – and differs from other oxicams in its rapid onset of action, high elimination rate. The drug is characterized by a pronounced analgesic effect and a favorable safety profile both in relation to the gastrointestinal tract and cardiovascular system, does not require dose adjustment in patients over 65 years of age.
Supporting agencies: This article has been supported by Stada.
About the Authors
E. Yu. Polishchuk
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Yurievna Polishchuk
34A, Kashirskoe shosse, Moscow 115522, Russia
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522, Russia
References
1. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya. 2018; 56(Suppl. 1):1-29. (In Russ.).
2. Berg J, Fellier H, Christoph T, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. doi: 10.1007/s000110050474.
3. Radhofer-Welte S, Dittrich P, Simin M, Branebjerg PE. Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. Clin Drug Investig. 2008;28(6):345-51. doi: 10.2165/00044011-200828060-00002.
4. Ankier SI, Brimelow AE, Crome P, et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J. 1988 Oct;64(756):752-4. doi: 10.1136/pgmj.64.756.752.
5. Coskun E, Dincer E, Turan G, Özgültekin A. Postoperative Analgesic Efficacy of Preemptive and Postoperative Lornoxicam or Tramadol in Lumbar Disc Surgery. Turk J Anaesthesiol Reanim. 2019 Oct;47(5):375-81. doi: 10.5152/TJAR.2019.60963. Epub 2019 May 20.
6. Martinez L, Ekman E, Nakhla N. Perioperative Opioid-sparing Strategies: Utility of Conventional NSAIDs in Adults. Clin Ther. 2019 Dec;41(12):2612-28. doi: 10.1016/j.clinthera.2019.10.002. Epub 2019 Nov 14.
7. Isola G, Alibrandi A, Pedullа E, et al. Analysis of the Effectiveness of Lornoxicam and Flurbiprofen on Management of Pain and Sequelae Following Third Molar Surgery: A Randomized, Controlled, Clinical Trial. J Clin Med. 2019 Mar 7;8(3):325. doi: 10.3390/jcm8030325.
8. Yakhno N, Guekht A, Skoromets A, et al. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. Clin Drug Investig. 2006;26(5):267-77. doi: 10.2165/00044011-200626050-00004.
9. Berry H, Bird HA, Black C, et al. A doubleblind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis. 1992 Feb; 51(2):238-42. doi: 10.1136/ard.51.2.238.
10. Goregaonkar A, Mathiazhagan KJ, Shah RR, et al. Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study. Curr Ther Res Clin Exp. 2009 Feb;70(1):56-68. doi: 10.1016/j.curtheres.2009.02.006.
11. Kidd B, Frenzel W. A multicenter randomized double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol. 1996 Sep;23(9):1605-11.
12. Rose P, Steinhauser C. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. doi: 10.2165/00044011-200424040-00004.
13. Caruso I, Montrone F, Boari L, et al. Lornoxicam versus diclofenac in rheumatoid arthritis: a double-blind, multicenter study. Adv Ther. 1994;11(3):132–8
14. Bernstein RM, Frenzel W. A comparative study of 2 dosage regimens of lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. Eur J Clin Res. 1995; 7:259-73
15. Pleiner J, Nell G, Branebjerg PE, et al. Safety of lornoxicam: an interim meta-analysis of comparative clinical trials. Eur J Pain. 2009;13(Suppl 1):191. doi: 10.1016/S1090-3801 (09)60662-5
16. Parada L, Marstein JP, Danilov A. Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016 Oct;6(5):445-54. doi: 10.2217/pmt.16.7. Epub 2016 Apr 18.
17. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.
18. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.
19. Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.
20. Temirkulova ShA, Imasheva SS, Zhagmarova LK, Nasyrova NZ. Experience of using xefocam in the treatment of osteoarthritis in patients with arterial hypertension (AH). Nauchno-prakticheskaya revmatologiya. 2006;(2):114. (In Russ.).
21. Vertkin AL, Naumov AV, Semenov PA, et al. Safety assessment of the use of lornoxicam and diclofenac sodium in general medical practice. Klinicheskaya Gerontologiya. 2009; 15 (2):21-6. (In Russ.).
22. Khripunova IG, Khripunova AA, Mnatsakanyan SG. Xefocam for pain relief in patients with osteoarthritis (OA). Nauchno-prakticheskaya revmatologiya. 2006;(2):119. (In Russ.).
Review
For citations:
Polishchuk EY, Karateev AE. Lornoxicam in the treatment of acute and chronic musculoskeletal pain. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(4):117-121. (In Russ.) https://doi.org/10.14412/1996-7012-2022-4-117-121
Views:
1292
Email this article 